The catecholamines adrenaline and noradrenaline are well known as the physiological trigger for hydrolyzing stored fat in adipose tissue so that it can be "burned" as fuel in other organs. Adrenaline is commonly referred to as the "fight or flight" hormone. This is because it orchestrates the body's defensive response for rapid recruitment of metabolic fuel from adipose tissue lipolysis, as well as to increase heart rate to enhance tissue perfusion so that organs such as skeletal muscle, and the heart itself, can extract, and metabolize that fuel. These catecholamines control fat cell metabolism in large part through activation of the β-adrenoceptors (βARs). The βARs are members of the large family of G protein-coupled receptors (GPCRs) that are integral membrane proteins of the plasma membrane. The three subtypes of βARs (β~1~AR, β~2~AR, and β~3~AR) are the products of different genes, and adipocytes express all three subtypes. In the mid-late 1980s the discovery of the β~3~AR subtype and selective ligands for this receptor led to a period of intense interest in this receptor. This was largely because of the powerful effect of selective β~3~AR agonists to promote energy expenditure and weight loss in animal models. However, the relatively poor preliminary performance of human β~3~AR agonists in clinical trials (Buemann et al., [@B7]; Arch, [@B1]) -- and the general belief that adult humans do not possess brown fat -- led to the termination of most such research programs.

β-Adrenoceptor activation promotes lipolysis of stored triglyceride in both white and brown adipocytes. In brown adipocytes there is a dense sympathetic nervous system (SNS) innervation and these fatty acids that are released function as both a fuel source and activators of the UCP1 protein, which permits mitochondrial respiration without ATP generation (as discussed elsewhere in this edited volume). Because of this high capacity for uncoupled oxidative respiration, BAT is capable of consuming considerable calories through non-shivering thermogenesis (Lean, [@B40]; Nedergaard et al., [@B54]). Its rich vasculature allows the dissemination of this heat to other organs. From detailed studies in rodents we know that prolonged cold acclimation, which increases SNS activation of BAT (and WAT), induces the appearance of brown adipocytes in *all* adipose depots typically considered to be WAT. Brown adipocytes can be found within several typical WAT depots including cervical, axillary, perirenal, periadrenal, and pericardiac depots (Kortelainen et al., [@B37]; Cinti, [@B13]). The increase in these cells involves branching and increased activity of the sympathetic nerve fibers within both BAT and WAT (Garofalo et al., [@B26]; Giordano et al., [@B28]; De Matteis et al., [@B20]; Cinti, [@B12], [@B13]). The essential role of the SNS in promoting the increased number and activity of these brown adipocytes is supported by data from mice deficient in the synthesis of noradrenaline or in βARs themselves (Thomas and Palmiter, [@B63]; Bachman et al., [@B3]; Jimenez et al., [@B33]). In these mutants, there is an absence of BAT that is replaced by WAT, and they tend to be obese. A similar loss of functioning BAT is observed in animals that have been maintained at thermoneutrality, a state in which there is little to no SNS activity in fat (Cinti, [@B12]). All together, these results suggest that β-agonists have the potential to promote postnatal changes in the WAT/BAT ratio. This could have profound implications, for example, in inducing weight loss in humans as is already observed in laboratory animals such as rodents as well as in adult dogs and rhesus monkeys (Arch et al., [@B2]; Champigny et al., [@B11]; Cousin et al., [@B18]; Himms-Hagen et al., [@B30]; Collins et al., [@B15]; Fisher et al., [@B23]). The latter two species, like humans, do not appear to retain large discrete depots of BAT in adulthood.

Signal Transduction Networks of βARs in Adipocytes
==================================================

A basic biochemical scheme for the stimulation of adipocyte metabolism by βARs is presented in Figure [1](#F1){ref-type="fig"}. In both brown and white adipocytes activation of βARs sets in motion the classic signaling paradigm in which the receptor interacts with the heterotrimeric GTP-binding protein Gs that, in turn, activates adenylyl cyclase to raise intracellular cAMP levels, the target of which is the cAMP-dependent protein kinase (PKA). In adipocytes PKA phosphorylates several proteins that decorate the lipid droplet (Brasaemle et al., [@B6]; Brasaemle, [@B5]; Bickel et al., [@B4]) as well as lipases that catalyze the hydrolysis of triglycerides (Lass et al., [@B39]). The interaction of these phosphorylated proteins at the lipid droplet surface culminates in the release of free fatty acids and glycerol and their export into the circulation to be consumed as fuel in other tissues. However, signal transduction through GPCRs, including the βARs, can consist of multi-component complexes capable of activating several kinase pathways either concurrently or sequentially (see Luttrell, [@B47] and Reiter and Lefkowitz, [@B58] for reviews).

![**Scheme for βAR signaling cascades controlling lipolysis in adipocytes**. βARs activate adenylyl cyclase through their coupling to the heterotrimeric Gs, producing cAMP (green dots) from ATP (yellow dots) to activate the cAMP-dependent protein kinase (PKA), allowing the catalytic subunits (PKA-C2) to be released from the holoenzyme that is anchored to the plasma membrane (AKAP). PKA phosphorylates (blue dots) lipases (HSL: hormone sensitive lipase) and lipid droplet binding proteins such as perilipins (Peri A; Peri B). Adipose triglyceride lipase (ATGL) is phosphorylated but not by PKA. The fatty acids released from triglyceride are chaperoned out of the cell by lipid binding proteins (aP2) and exported through fatty acid transport proteins (FATP).](fendo-02-00102-g001){#F1}

PKA is a well-established downstream agent of the βARs. However, other kinases are also activated by βARs in adipocytes such as ERK, p38 MAP, and AMP kinases (Collins et al., [@B14]; Gauthier et al., [@B27]; Omar et al., [@B55]). The activation of these other kinase classes sometimes depends directly upon PKA, while for others a connection to PKA exists only as a consequence of its lipid mobilizing effects (Gauthier et al., [@B27]). In addition, PKA in adipocytes is largely Type II, denoting its relative sensitivity to ambient cAMP levels as compared to Type I (Corbin et al., [@B17]). In adipocytes PKA is also membrane-anchored through interaction with the A-kinase anchoring proteins (AKAPS; McConnachie et al., [@B50]). Thus there are spatial aspects to PKA activation to consider as well. In that regard an interesting new report identifies optic atrophy-1 (OPA1), a protein best known for its role in mitochondrial "quality control", as an AKAP targeting PKA to the lipid droplet to facilitate perilipin phosphorylation and activation of lipolysis (Pidoux et al., [@B57]).

G protein-coupled receptors coupled to heterotrimeric Gi antagonize the activation of adenylyl cyclase in response to βARs. With the discovery that GPCRs coupled to Gi can also activate the ERK MAP kinase pathway (Daub et al., [@B19]; van Biesen et al., [@B67]), we now know that the picture is a bit more complex. Another dimension to this signaling is that GPCRs can, under certain circumstances, couple to more than one G protein. This is relevant to βAR signaling in adipocytes in that β~2~AR was shown to activate ERK following their phosphorylation by PKA. As shown in Figure [2](#F2){ref-type="fig"}, this phosphorylation diminishes β~2~AR coupling to Gs and increases coupling to Gi (Zamah et al., [@B73]; Martin et al., [@B49]). Figure [2](#F2){ref-type="fig"} also shows that this signaling pathway includes additional phosphorylation events by GPCR kinases (GRKs), which triggers the binding of β-arrestin (Lefkowitz et al., [@B41]): a scaffolding molecule first shown to be involved in the desensitization of β~2~AR to terminate its activation of adenylyl cyclase (Lohse et al., [@B45]). Subsequently, Luttrell et al. ([@B48]) showed that β-arrestin has broader roles; first showing that it could recruit Src kinase into a complex that leads to ERK activation through proline-rich regions that bind the SH3-domain of Src (see Figure [2](#F2){ref-type="fig"}).

![**βARs activate ERK MAPK in addition to PKA: the β~2~AR mechanism as an example**. Upon catecholamine activation, PKA is activated (step 1), and phosphorylates the receptor at intracellular sites (red circles; step 2a). The receptor is also phosphorylated by G protein-coupled receptor kinase (GRK) at multiple sites in the C-terminus (step 2b). PKA phosphorylation interdicts interaction with Gs to favor Gi, while GRK recruits β-arrestin, promoting ERK activation (step 3). β~2~AR is subject to rapid desensitization and internalization (step 4), whereupon phosphatases remove the phosphates and the receptor is recycled back to the plasma membrane.](fendo-02-00102-g002){#F2}

Functionally this aspect of βAR signaling is important for adipocytes because βAR activation of ERK is responsible for about 20--25% of lipolysis (Greenberg et al., [@B29]; Robidoux et al., [@B60]). β~3~AR in particular is interesting in this regard because it can activate both PKA and ERK by interacting with Gs and Gi interchangeably in the absence of receptor phosphorylation and β-arrestin (Liggett et al., [@B43]; Soeder et al., [@B62]). Instead, we identified a novel mechanism by which β~3~AR is able to activate ERK. As illustrated in Figure [3](#F3){ref-type="fig"}A, β~3~AR contains clusters of proline motifs in the two most important intracellular regions of a GPCR: the third intracellular loop and the carboxyl terminus. These prolines are arranged in the PXXP motif that serves as agonist-dependent docking sites for the SH3-domain of Src. The ability of β~3~AR to directly recruit Src kinase in adipocytes is shown in Figure [3](#F3){ref-type="fig"}B (adapted from Cao et al., [@B9], and see legend). The β~3~AR-selective agonist CL316243 (CL), triggers ERK activation via the endogenous β~3~AR in non-transfected (*NT*) cells, and in cells transfected with HA-tagged mouse β~3~AR. In the presence of pertussis toxin (PTX), ERK activation was abolished, indicating the requirement for signaling through the heterotrimeric Gi. Figure [3](#F3){ref-type="fig"}B shows that Src kinase co-precipitates with the HA-β~3~AR, and this interaction is both β~3~-agonist and Gi-dependent. As shown further by Cao et al. there are three to four of these PXXP motifs within all the species homologs of β~3~AR, but perturbations of only one or two of these are enough to eliminate ERK activation (Cao et al., [@B9]; Kumar et al., [@B38]). These results suggested that there could perhaps be other molecules in addition to Src that might be recruited to the receptor as part of a larger complex. A proteomic search for proteins that could be co-immunoprecipitated with the β~3~AR from adipocytes in an agonist-dependent manner identified several proteins that interact with the receptor and the proline motifs, among which was the intermediate filament protein vimentin (Kumar et al., [@B38]). Vimentin is a component of the lipid droplet in adipocytes (Franke et al., [@B24]), and was found to be required in adipocytes for both ERK activation and lipolysis (Kumar et al., [@B38]). Several aspects of this mechanism as well as its significance remain incomplete. These include (i) knowledge of the target(s) of ERK that are responsible for lipolysis; (ii) the mechanism by which vimentin is recruited to the β~3~AR, since it does not possess an SH3 binding domain, and therefore perhaps requires a protein intermediate; (iii) the relative importance of ERK in lipolysis in human adipocytes; (iv) what other events might be regulated by this βAR-ERK pathway in adipocytes, such as the control of adipose-secreted factors as one example. Finally, the function of this βAR-activated ERK pathway in brown adipocytes and the role of insulin in these effects has been partly investigated (Klein et al., [@B35]; Lindquist et al., [@B44]; Fasshauer et al., [@B22]) but much work remains to be done both mechanistically and in physiological terms to understand their roles and impact.

![**A unique dual signaling mechanism by β~3~AR**. **(A)** The receptor can couple to both Gs and Gi to activate PKA (step 1a) and ERK (step 1b). The shaded gray arrows point to subsequent downstream cellular effects. **(B)** Preadipocytes were transfected or not (NT) with hemagglutinin (HA)-tagged β~3~AR and differentiated. **(a)** Expression of aP2 and β~3~AR mRNA as a function of differentiation on the indicated days. Levels of aP2 are maximal by day 4. Cyclophilin RNA (*Cyclo*) is the internal control. **(b)** Phospho-ERK1/2 in cell lysates in response to the β~3~AR agonist CL316243 (CL) in the absence or presence of pertussis toxin (PTX; *n* = 3; mean ± SD). **(c)** Level of c-Src co-precipitated with β~3~AR (*n* = 3; mean ± SD). (Adapted from Cao et al., [@B9]).](fendo-02-00102-g003){#F3}

In addition to ERK, other MAPK kinases are also activated in response to βARs in adipocytes. p38 MAPK is activated by βARs in white (Moule and Denton, [@B52]; Mizuno et al., [@B51]) and brown adipocytes (Cao et al., [@B10]), including human adipocytes (Figure [4](#F4){ref-type="fig"}). As shown in Figure [5](#F5){ref-type="fig"}, we showed that p38 MAPK activation is indirectly dependent on PKA. An interesting aspect of βAR-dependent activation of MAPKs in adipocytes is that JNK is not activated by βARs or cAMP (Robidoux et al., [@B59]). Important downstream targets of this pathway in brown adipocytes are the transcription of the *Ucp1* and *PGC-1*α genes (Cao et al., [@B10], [@B8]). Later work proposed p38 MAPK as one of the discriminating factors in the ability of certain mouse strains such as A/J to increase brown adipocyte numbers in WAT during early postnatal growth and development (Xue et al., [@B71]). p38 MAPK has also been implicated as a downstream factor in the reported permissive property of BMP7 to contribute to brown adipocyte differentiation (Tseng et al., [@B64]). If we think about how the three βARs activate the same pathways, it becomes clear that although the pathways are the same, the timing of the signaling is not necessarily identical, and signal strength can also be affected. For example, β~3~AR sacrifices amplitude of cAMP generation to gain the ability to generate two signaling pathways simultaneously. These concepts are illustrated in Figure [6](#F6){ref-type="fig"}.

![**β-agonists increase activation of p38 MAPK in cultured human subcutaneous adipocytes**. **(A)** Western blot measuring isoproterenol (Iso) concentration-response for phospho-p38 MAPK (P-p38). **(B)** Western blot comparing P-p38 response to 15 min treatment with Iso, EGF and the positive control cell stressor Anisomycin. All samples shown are independent biological replicates.](fendo-02-00102-g004){#F4}

![**βAR activation of thermogenesis through p38 MAPK**. Direct targets of p38 MAPK include peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) and ATF-2. These target the genes for *Pgc-1*α and *Ucp1*. The tandem arrows between PKA and the MAPK module are not yet biochemically defined.](fendo-02-00102-g005){#F5}

![**Signaling networks of the βARs in adipocytes**. Each of the three βARs is able to activate similar pathways: PKA, ERK, and p38 MAPK. However the order and number of steps involved varies, such that β~3~AR represents what we term "concurrent" coupling to Gs vs. Gi, vs. the β~2~AR type of "processive" coupling. Less is known about the details of β~1~AR. Because β~1~AR also contains one of the PXXP motifs as in β~3~AR, but it is also phosphorylated, we have provisionally termed in "mixed-mode" coupling. The shaded gray arrows point to subsequent downstream cellular effects.](fendo-02-00102-g006){#F6}

Mechanistically, the signaling components between PKA and p38 MAPK are not understood, although we have made some progress toward this goal. It appears that p38α MAPK, but not p38β MAPK, is activated in brown adipocytes downstream of βARs and PKA, and that the immediate upstream kinase appears to specifically be MKK3 (Robidoux et al., [@B59]). In addition, although this βAR → PKA → p38 MAPK pathway also exists in white adipocytes (including human adipocytes) the downstream functional consequences are as yet unknown. We generated mice with adipose-specific deletion of p38α to uncover the role of PKA-dependent p38α MAPK activation in white adipocytes. In the absence of p38α in adipocytes, preliminary evidence suggests that JNK now becomes active, similar to observations made for some other tissue-specific deletions of p38α MAPK (Hui et al., [@B31]; Perdiguero et al., [@B56]; Ventura et al., [@B68]; Wada et al., [@B69]). Inappropriate JNK activation that occurs in other metabolic tissues such as muscle, liver, and fat has been associated with insulin resistance (Vallerie et al., [@B66]). Therefore, the complete characterization of these mice will hopefully fill in these gaps in our understanding of the mechanism(s) and physiological interplay between p38 MAPK and JNK in adipocytes and the mechanisms of their control.

Within the last couple of years there has been increasing evidence that AMPK is activated in adipocytes in response to lipolytic stimuli such as βARs (Hutchinson et al., [@B32]; Koh et al., [@B36]; Mulligan et al., [@B53]; Gauthier et al., [@B27]; Omar et al., [@B55]). AMPK activation is not necessarily a result of direct involvement of PKA but appears to be more related to lipolysis itself and its effect in reducing the net ATP levels within adipocytes. These findings suggest that lipolysis results in the increase in cellular energy consumption and this is proposed to be due to the stimulation of energy consuming processes such as fatty acid re-esterification and even mitochondrial uncoupling (Gauthier et al., [@B27]; Yehuda-Shnaidman et al., [@B72]).

Uncovering Pathways that Silence or Repress Energy Expenditure in Brown Adipocytes
==================================================================================

We spend much effort trying to understand how to "stimulate" or "activate" and "turn on" catabolic pathways such as adaptive thermogenesis in brown adipocytes. However, if there are active mechanisms of repression, we need to identify them in order to release the "brake." Certain targeted gene disruptions in mice that result in a lean phenotype have provided some clues to such repressive pathways. Some of these genes include p70 S6 kinase (Um et al., [@B65]), estrogen related receptor-α (Luo et al., [@B46]), co-repressor RIP140 (Leonardsson et al., [@B42]), the liver X receptors (LXR; Kalaany et al., [@B34]), and others (Dong et al., [@B21]; Gao et al., [@B25]). Although the connections that may exist between these factors are not clear, mechanistically we have uncovered an interesting role at least for the nuclear factors LXRα and RIP140 to function as a regulated repressor complex that blocks βAR-stimulated *Ucp1* gene expression (Wang et al., [@B70]; Collins et al., [@B16]). Specifically, LXRα recruits the co-repressor RIP140 to a DR-4 element in the *Ucp1* enhancer adjacent to the PPAR/RXR binding DR-1 motif, leading to suppression of *Ucp1* gene transcription. Given the common target and interaction between LXR and RIP140, we can link the phenotype of these individual mutations to a common mechanism. A necessary element for this repression by LXRα appears to be the availability of an LXR ligand. While the nature of these ligands and the enzymes that control their production are still a matter of much debate (Russell, [@B61]), at least one suggested candidate, cholesterol-25-hydroxylase, is expressed in white adipocytes at a level 30 times higher than in brown adipocytes (Wang et al., [@B70]). Therefore, this potential point of control will be an important feature to further explore. Since the ability to expand these reservoirs of "novel" brown adipocytes *in vivo*, to mobilize fuel and to activate thermogenesis all depend on the catecholamine stimulation of βARs, our understanding of the signaling mechanisms of these receptors, and how they themselves are regulated, will be a key factor in harnessing the capacity for increasing these "plastic" brown adipocytes.

Conclusion
==========

Although much is known about the signal transduction mechanism of βARs, the future ahead is still full of work to be done. Undoubtedly more surprises will be in store for us as we continue to uncover the signaling networks that βARs control in adipocytes and how we might be able to take advantage of this new knowledge to therapeutically intervene in combating the epidemic of metabolic disease in our midst.
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